In conventional pharmaceutical operating models, bioengineering is a procured service. Expression systems, delivery platforms, and biomanufacturing process engineering are contracted to CROs and CDMOs, with the sponsor company owning the IP on the therapeutic asset but not on the platform that produced it.
This works at scale, but it has structural costs:
- IP fragmentation. The platform IP, often the most defensible and reusable asset, sits with vendors who can license it to competitors.
- Process re-engineering friction. Every new programme requires re-establishing process knowledge with the next vendor, with significant time and cost penalty.
- Capital-allocation rigidity. Sponsor companies pay vendor margins on every batch, in perpetuity, on assets whose underlying platforms they could have owned outright.
Alifarc was structured with bioengineering as the central pillar of the platform, not as a procured service. The areas of business include pharmaceutical development and manufacture, but they are anchored to a bioengineering platform that the company owns.
What this looks like in practice
- Expression and delivery systems developed in-house, with IP retained by the company.
- Biomanufacturing process engineering held as a platform capability that scales across multiple therapeutic programmes.
- Scientific consulting on bioengineering design: externalised as a revenue line where appropriate, but never at the cost of platform ownership.
The thesis is not that every pharmaceutical company should own its bioengineering. It is that for a company being built now, with a multi-decade horizon and a multi-jurisdictional manufacturing footprint, the platform is the asset that compounds.
The therapeutic candidates that come out of the platform will be discussed under separate communications, in due course and with appropriate institutional readers under NDA.